ALLMedicine™ Hirsutism Center

Jun 24th, 2022 - To determine depression symptoms and quality of life in women with polycystic ovary syndrome (PCOS). The data were collected using the Participant Information Form, PCOS Quality of Life Questionnaire (PCOSQ-50), and Beck Depression Inventory (BDI)...

Jun 23rd, 2022 - Reference Range The reference range of urinary 17-hydroxyprogesterone (17-OHPG) in children is as follows: [1, 2, 3] Age 3 days to 1 year: Up to 50 ng/24 hours Age 1-8 years: Up to 300 ng/24 hours The following is the reference of urinary 17-OHPG ...

Jun 23rd, 2022 - The reference range of urinary 17-hydroxyprogesterone (17-OHPG) in children is as follows:[1, 2, 3] Age 3 days to 1 year: Up to 50 ng/24 hours Age 1-8 years: Up to 300 ng/24 hours The following is the reference of urinary 17-OHPG in adults: Males:...

Jun 23rd, 2022 - Reference Range The reference range of urinary 17-hydroxyprogesterone (17-OHPG) in children is as follows: [1, 2, 3] Age 3 days to 1 year: Up to 50 ng/24 hours Age 1-8 years: Up to 300 ng/24 hours The following is the reference of urinary 17-OHPG ...

Jun 10th, 2022 - Hypertrichosis and hirsutism can be signs of underlying conditions, some of which may be life-threatening. They also can result in significant psychosocial distress for patients. Hypertrichosis refers to excessive hair growth beyond normal variati...

Mar 10th, 2018 - To update the "Evaluation and Treatment of Hirsutism in Premenopausal Women: An Endocrine Society Clinical Practice Guideline," published by the Endocrine Society in 2008. The participants include an Endocrine Society-appointed task force of seven...

Nov 9th, 2011 - Hirsutism, defined by the presence of excessive terminal hair in androgen-sensitive areas of the female body, is one of the most common disorders in women during reproductive age. We conducted a systematic review and critical assessment of the ava...

Feb 7th, 2008 - Our objective was to develop clinical practice guidelines for the evaluation and treatment of hirsutism in premenopausal women. The Task Force was composed of a chair, selected by the Clinical Guidelines Subcommittee (CGS) of The Endocrine Society...

Jun 2nd, 2022 - Our work is an observational analytic cross-sectional study that included an Egyptian convenient sample of 186 females with primary infertility due to polycystic ovary syndrome. Patients aged 18-35 were recruited from Kasr Al-Ainy Gynecology Clini...

May 19th, 2022 - Polycystic ovary syndrome (PCOS), is the most common endocrinological disorder that affects the reproductive aged women. In addition to causing problems such as menstrual irregularity, hirsutism, acne, it is also an important health problem that c...

May 18th, 2022 - Aim 1. Examine mechanisms of subcutaneous abdominal adipose (fat) development in normal-weight PCOS women vs. BMI- and age-matched normal (control) women. Subjects and clinical assessment: We will recruit 16 lean (18.5-25 kg/M2) PCOS subjects and ...

May 17th, 2022 - This project aims to compare "diet" and "diet and exercise combination" interventions in obese women with polycystic ovary syndrome. This project will be carried out in the Dokuz Eylül University Research and Application Hospital gynecology outpat...

May 16th, 2022 - Cornelia de Lange syndrome (CdLS) is a genetic condition caused by mutations in cohesin-related genes, mostly notably NIPBL. The CdLS phenotype includes physical features such as typical facies, limb abnormalities, short stature, and hirsutism as ...

Jun 8th, 2022 - Women with polycystic ovary syndrome (PCOS) have an increased risk for several diseases and symptoms, many independent of body mass index (BMI), new research indicates. Some diseases are linked for the first time to PCOS in this study, the authors.

Feb 22nd, 2022 - Spironolactone was not associated with any meaningful increase in the risk of breast cancer or other solid organ cancers in a systematic review and meta-analysis covering seven observational studies and a total population of over 4. 5 million peopl.

Jan 28th, 2022 - Patients with relapsed or corticosteroid-resistant immune thrombocytopenia (ITP) had a 33% higher response rate and 50% increase in sustained responses with all-trans retinoic acid (ATRA) plus low-dose rituximab (Rituxan), Chinese investigators re...

Jan 4th, 2022 - The US Food and Drug Administration has approved levoketoconazole (Recorlev, Xeris Biopharma) for the treatment of endogenous hypercortisolemia in adults with Cushing syndrome for whom surgery is not possible or was not curative. Endogenous Cushin...

Dec 16th, 2021 - The FDA granted accelerated approval for the first drug to reduce proteinuria in primary immunoglobulin A (IgA) nephropathy, the agency announced on Wednesday. The delayed released budesonide (Tarpeyo) capsules are indicated to lower increased pro...